Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-29

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes.

PURPOSE: This phase II trial is studying how well letrozole works in treating women with ductal carcinoma in situ.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ

NCT00290745

Breast Cancer

COMPLETED PHASE1/PHASE2

Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.

NCT02010021

Breast Cancer

COMPLETED NA

Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

NCT03497702

Breast Cancer Invasive Breast Cancer

UNKNOWN PHASE2

89ZrTrastuzumab Breast Imaging With Positron Emission Tomography

NCT02065609

Breast Cancer

COMPLETED EARLY_PHASE1

Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer

NCT00375752

Breast Neoplasms

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Treatment with letrozole begins within 21 days of registration, and only after notification has been received from the UCSF Breast MRI Research Laboratory that the baseline MRI is acceptable. Protocol therapy will consist of 6 months of letrozole, administered orally at a dose of 2.5 mg/day. Patients will have a MRI for disease evaluation at months 3 and 6. All patients will continue to take study drug until the day prior to surgery, whether at month 3 or at month 6 or may stop if they experience unacceptable toxicity. It is expected that decisions regarding any adjuvant treatment (eg, radiation and hormonal therapy) will be made individually based on the best practice guidelines, using informed and shared decision making between patient and provider. The primary and secondary objectives are provided below.

Primary objective:

1\. To estimate the mean change in MRI tumor volume from pretreatment to completion of preoperative endocrine therapy in estrogen receptor-positive (ER+) ductal carcinoma in situ (DCIS), as well as to determine whether 3-month change in volume correlates with 6-month change.

Secondary objectives:

1. To assess radiographic-pathologic correlation between MRI findings and histopathology, including the prevalence of occult invasive cancer in patients undergoing neoadjuvant endocrine therapy for DCIS.
2. To compare changes in MRI maximum lesion diameter and mammographic extent at baseline and following treatment. These are two additional radiographic parameters which may also biological response to therapy.
3. To determine practice patterns of adjuvant hormonal and radiation therapy in patients who complete neoadjuvant letrozole therapy for DCIS.
4. To determine whether Ki67 is reduced with neoadjuvant letrozole treatment for DCIS, and to compare the reduction in proliferation between radiographic responders and non-responders.
5. To identify baseline IHC and expression biomarkers predictive of response to treatment, with response determined by extent of Ki67 reduction. Subsets showing the greatest reduction in Ki67 would be the most likely candidates for non-operative treatment in future studies.
6. To examine whether germline polymorphisms are associated with clinical endpoints, including treatment-related toxicity or efficacy outcomes, or with expression of biomarkers in serum or tumor.
7. To assess quality-of-life and musculoskeletal symptoms associated with neoadjuvant letrozole for ER positive DCIS.

Patients will be followed up to 6 months post-surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

letrozole + MRI + surgery

Patients receive letrozole (2.5 mg) one tablet each day after confirmation that the MRI is acceptable. There is a 3 and 6 month disease evaluation by MRI of both breasts. If the DCIS has grown, the patient will have surgery to remove it and will continue to take letrozole until the day before surgery. It is expected that decisions regarding any adjuvant treatment will be made individually based on best practice guidelines, using informed and shared decision making between the patient and provider.

Group Type EXPERIMENTAL

letrozole

Intervention Type DRUG

MRI

Intervention Type PROCEDURE

conventional surgery

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

letrozole

Intervention Type DRUG

MRI

Intervention Type PROCEDURE

conventional surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with microinvasion on diagnostic core biopsy, defined as tumor ≤ 1 mm in greatest dimension, will be allowed to participate.
2. All patients must have a clip placed, either at the time of the diagnostic biopsy or at the time of the baseline MRI prior to the start of treatment.
2. Tissue samples: Patient has diagnostic tissue available for correlative studies.
3. Clinical stage: Tis or T1mi N0, M0
4. Hormone receptor status: DCIS must express estrogen and/or progesterone receptor, as determined by immunohistochemical methods on the diagnostic pathology sample, according to the local institution's standard protocol. Greater than or equal to 1% cells will be considered to be positive.
5. Menopausal status: Patients must be postmenopausal defined as:

1. Age ≥ 55 years and one year or more of amenorrhea
2. Age \< 55 years and one year or more amenorrhea, with an estradiol assay \< 20pg/ml
3. Surgical menopause with bilateral oophorectomy (at least 28 days must elapse from surgery to time of study registration)

The use of GnRH analogs to achieve post menopausal status is not allowed.
6. Prior treatment:

1. No prior surgical excision in the index breast for current DCIS diagnosis of DCIS
2. Any exogenous hormone therapy must be completed 4 weeks prior to registration
3. Any patients with a history of tamoxifen or raloxifene use within two years of current DCIS diagnosis are not eligible
4. No prior neoadjuvant/adjuvant therapy for current DCIS diagnosis
7. Contraindication to MRI: No contraindications to breast MRI
8. Measurable disease: Mammographic extent of calcifications must be accurately measurable in at least one dimension with each lesion ≥ 1 cm and ≤ 7 cm

1. DCIS must be visible on MRI based on central review.
2. Patients with palpable DCIS or adenopathy are not eligible to participate.
3. Patients with multifocal or bilateral disease are eligible.
9. History of osteoporosis: Women diagnosed with osteoporosis may participate in this trial provided they are receiving appropriate therapy or if they have declined therapy.
10. Age: Patients ≥ 18 years of age
11. Performance Status: ECOG performance status 0 or 1
12. Pregnancy/nursing status: Not pregnant or nursing
13. Required Initial Laboratory Values:

1. ANC ≥ 1,000/μL
2. Platelet count ≥ 100,000/μL
3. Serum creatinine ≤ 1.7 mg/dL
4. Bilirubin ≤ 2.0 mg/dL
5. AST/ALT ≤ 2.5 times upper limit of normal
6. Serum estradiol level assay \< 20 pg/mL \*Required for patients \< 55 years of age and one year or more of amenorrhea

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shelley Hwang, MD, MPH

Role: STUDY_CHAIR

Duke University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cedars Sinai Medical Center

Los Angeles, California, United States

Site Status

Bay Area Tumor Institute

Oakland, California, United States

Site Status

UCSF Medical Center-Mount Zion

San Francisco, California, United States

Site Status